Vancouver’s Aspect Biosystems announced a $72.75 million investment from the Governments of Canada and British Columbia to support a $200 million project advancing their bioprinted tissue therapeutics. This funding will enhance Aspect’s biomanufacturing capabilities and therapeutic platform, targeting incurable diseases with innovative treatments.
Aspect’s collaboration with Novo Nordisk will be leveraged, focusing on diabetes, obesity, liver disease, and other metabolic disorders. CEO Tamer Mohamed emphasized the investment as a crucial step in regenerative medicine.
Want to know more? Check out the source code on Techcouver.